Clinical trials: Persistent Cervical Cancer
Esophagogastric Tumors, Gastric Cancer
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
The purpose of this study is to find out whether treatment with trastuzumab combined with pembrolizumab will improve the clearance of tumor DNA from participants' bodies after surgery.
- Conditions
- Esophagogastric Tumors, Gastric Cancer, Gastric Tumor, Esophageal Cancer
- Trial name
- NCT04510285
- Testing
- Trastuzumab, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
This is an open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccines delivered by electroporation (EP) to female participants with HPV-16 and/or 18-positive cervical carcinoma.
- Trial name
- NCT02172911
- Testing
- INO-3112, CELLECTRA™-5P
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Inovio Pharmaceuticals
Cervical Cancer
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00691301
- Testing
- cisplatin, pemetrexed disodium
- Where
- 12 sites in United States
- Volunteers
- 55 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer
GSK1120212+GSK2141795 for Cervical Cancer
This research study is evaluating the combination of two drugs called GSK1120212 (trametinib) and GSK2141795 as a possible treatment for recurrent or persistent cervical cancer.
- Trial name
- NCT01958112
- Testing
- GSK1120212 (trametinib), GSK2141795
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00122681
- Testing
- Cervarix™, Havrix™-based investigational formulation
- Where
- 138 sites in United States, Australia and 12 more
- Volunteers
- 18,729 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
This randomized phase III trial studies the side effects of paclitaxel when given together with cisplatin or topotecan with or without bevacizumab and to compare how well they work in treating patients with stage IVB, cervical…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
- Trial name
- NCT00803062
- Testing
- Bevacizumab, Cisplatin, Laboratory Biomarker Analysis
- Where
- 549 sites in United States, Spain
- Volunteers
- 452 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00248560
- Testing
- docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent cancer of the cervix. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
- Trial name
- NCT00025233
- Testing
- bevacizumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
The purpose of this study is to determine whether the combination of topotecan, cisplatin and bevacizumab is effective in the treatment of recurrent or persistent cervical cancer
- Trial name
- NCT00548418
- Testing
- Topotecan, Cisplatin, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7
- Trial name
- NCT02257528
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- 331 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)